Sol Gel Technologies (NASDAQ:SLGL) received a $21.00 price objective from analysts at HC Wainwright in a report issued on Wednesday, TipRanks reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 194.12% from the stock’s current price.
A number of other equities analysts have also recently commented on the stock. ValuEngine cut shares of Sol Gel Technologies from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. Zacks Investment Research cut shares of Sol Gel Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 19th.
NASDAQ SLGL traded down $0.24 on Wednesday, reaching $7.14. The company had a trading volume of 25,400 shares, compared to its average volume of 11,889. The company has a market cap of $139.61 million, a P/E ratio of -3.97 and a beta of 0.82. Sol Gel Technologies has a 12 month low of $5.41 and a 12 month high of $10.24.
Sol Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.82). The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.05 million. Sol Gel Technologies had a negative net margin of 20,190.54% and a negative return on equity of 58.33%. As a group, equities analysts anticipate that Sol Gel Technologies will post -1.99 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Sol Gel Technologies stock. Delek Group Ltd. increased its position in shares of Sol Gel Technologies Ltd (NASDAQ:SLGL) by 9.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,429,761 shares of the company’s stock after purchasing an additional 128,796 shares during the period. Delek Group Ltd. owned approximately 7.56% of Sol Gel Technologies worth $8,838,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.07% of the company’s stock.
Sol Gel Technologies Company Profile
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Featured Article: What is a Futures Contract?
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.